Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 135, Issue 4, Pages 820-829Publisher
WILEY-BLACKWELL
DOI: 10.1002/ijc.28711
Keywords
TLR7; immunotherapy; radiotherapy; combination therapy; murine tumor model
Categories
Funding
- AstraZeneca
- Biotechnology and Biological Sciences Research Council
- Cancer Research UK
- Leukemia and Lymphoma Research
- Medical Research Council [G0500366]
- MRC [G0500366] Funding Source: UKRI
- Cancer Research UK [11335, 16397] Funding Source: researchfish
- Medical Research Council [G0500366] Funding Source: researchfish
Ask authors/readers for more resources
Although topical TLR7 therapies such as imiquimod have proved successful in the treatment of dermatological malignancy, systemic delivery may be required for optimal immunotherapy of nondermatological tumors. We report that intravenous delivery of the novel small molecule TLR7 agonist, DSR-6434, leads to the induction of type 1 interferon and activation of T and B lymphocytes, NK and NKT cells. Our data demonstrate that systemic administration of DSR-6434 enhances the efficacy of ionizing radiation (IR) and leads to improved survival in mice bearing either CT26 or KHT tumors. Of the CT26 tumor-bearing mice that received combined therapy, 55% experienced complete tumor resolution. Our data reveal that these long-term surviving mice have a significantly greater frequency of tumor antigen specific CD8(+) T cells when compared to age-matched tumor-naive cells. To evaluate therapeutic effects on spontaneous metastases, we showed that combination of DSR-6434 with local IR of the primary tumor significantly reduced metastatic burden in the lung, when compared to time-matched cohorts treated with IR alone. The data demonstrate that systemic administration of the novel TLR7 agonist DSR-6434 in combination with IR primes an antitumor CD8(+) T-cell response leading to improved survival in syngeneic models of colorectal carcinoma and fibrosarcoma. Importantly, efficacy extends to sites outside of the field of irradiation, reducing metastatic load. Clinical evaluation of systemic TLR7 therapy in combination with IR for the treatment of solid malignancy is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available